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Abstract
Background Next-generation sequencing gene panels
are increasingly used for genetic diagnosis in inherited
cardiac diseases. Besides pathogenic variants, multi-
ple variants, variants of uncertain significance (VUS)
and incidental findings can be detected. Such test re-
sults can be challenging for counselling and clinical
decision making.
Methods We present patient cases to illustrate the
challenges that can arise when unclear genetic test
results are detected in cardiogenetic gene panels.
Results We identified three types of challenging gene
panel results: 1) one or more VUS in combination with
a pathogenic variant, 2) variants associated with an-
other genetic heart disease, and 3) variants associated
with a syndrome involving cardiac features.
Conclusion Large gene panels not only increase the
detection rates of pathogenic variants but also of vari-
ants with uncertain pathogenicity, multiple variants
and incidental findings. Gene panel results can be
challenging for genetic counselling and require proper
pre-test and post-test counselling. We advise evalua-
tion of challenging cases by a multidisciplinary team.
Keywords Next-generation sequencing · Variants of
unknown significance · Cardiogenetics · Gene panel ·
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Introduction
In inherited cardiac diseases next-generation se-
quencing (NGS) techniques with sequencing and
analysis of multiple genes in a single experiment have
become standard diagnostic care [1]. In the Nether-
lands, large gene panels analysing over 50 genes are
offered for cardiomyopathies and for primary arrhyth-
mia syndromes. Testing more genes using a gene
panel or other NGS-based technique not only in-
creases the detection rate of disease-causing variants,
but also of variants of uncertain/unknown signif-
icance (VUS). VUS are variants whose implication
with disease cannot be concluded based on current
data. With time and further knowledge, VUS can
then be classified as either benign without clinical
significance or disease-causing.
With the more frequent use of NGS, genetic coun-
sellors are increasingly being confronted with VUS.
The goal of genetic testing is to provide the patient
with more certainty about disease and prognosis, and,
more importantly, in the case of genetic heart disease,
to identify relatives at risk and enable possible treat-
ments or preventive measures [2, 3]. The detection of
a VUS clearly does not provide the genetic counsellor,
What’s new?
 Interpretation of genetic variants of unknown
significance, multiple variants or incidental find-
ings can be challenging.
 Doctors should be aware of these challenges and
discuss them during pre-test counselling with
their patient.
 It is important that challenging genetic test re-
sults are reviewed by a multidisciplinary team.
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the patient and his/her family with the desired cer-
tainty and the possibility of genetic cascade screening
in relatives [4–8]. Interpretation and counselling
can be even more challenging for clinicians without
proper training in medical genetics, such as oncol-
ogists, cardiologists, or general practitioners, who
may increasingly request NGS [9, 10]. Besides VUS,
other unclear or unexpected findings can be detected
using NGS-based techniques, such as multiple vari-
ants with different suspicions of pathogenicity and
incidental findings (i. e. findings not related to the
disease for which the test is requested). We use pa-
tient cases to illustrate different clinical challenges
that derived from the cardiogenetic gene panel re-
sults. A separate article describes the yield of the




Patients and family members were counselled and
tested at the Cardiogenetics outpatient clinic of the
Amsterdam UMC, University of Amsterdam, in a mul-
tidisciplinary setting including a detailed review of
medical history, family history, cardiac evaluations,
and counselling on possible outcomes of the gene
panel for the patient and his/her relatives, including
the possibility of detection of one or more VUS. We
selected patients with an unclear test result of a car-
diomyopathy or arrhythmia gene panel to illustrate
the challenges associated with detection of variants
with less clear pathogenicity. After an unclear genetic
test result cases were discussed in a multidisciplinary
team. All patients and family members gave informed
consent for the anonymous use of their genetic data.
The patients and families presented in the cases have
been anonymised and partly changed to prevent iden-
tification.
NGS-based cardiogenetic gene panel analyses and
interpretation and classification of detected variants
Detailed information on the NGS-based gene panels
is available in the accompanying article describing
the yield in this issue and its online Supplemen-
tary File 1 [11]. Variants detected in a cardiogenetic
gene panel in our laboratory are reported using
Human Genome Variation Society nomenclature
guidelines (http://www.hgvs.org/mutnomen) and
classified into one of five categories (class 1: certainly
not pathogenic, class 2: unlikely pathogenic, class 3:
unknown pathogenicity (also called VUS), class 4:
likely pathogenic; class 5: (certainly) pathogenic) us-
ing the classification criteria indicated in the online
Supplementary File 1. Identified class 1 and 2 variants
are not reported to the requesting physician.
Results
Although both genetic counsellors and patients were
aware of the possibility of VUS detection and asso-
ciated uncertainty, they encountered challenges in
counselling and clinical decision making in some pa-
tients. Here, we describe three types of challenges
in counselling/clinical decision making derived from
the gene panel results.
VUS in a syndromic gene
A middle-aged female with idiopathic dilated car-
diomyopathy (DCM) and a family history of pre-
mature sudden cardiac death was tested using the
cardiomyopathy gene panel. We identified a class 3
variant in the GLA gene (c.1153A>G; p.(Thr385Ala),
NM_000169.2). The variant changes a moderately
conserved amino acid (PolyPhen HumDiv= 0.708 and
HumVar= 0.122) and the chemical difference between
Thr and Ala is small (Grantham distance: 58 (0–215)).
At the time of the test result this variant had not
been described in over 10,000 control alleles. The
GLA gene on the X-chromosome is one of the genes
on the cardiomyopathy gene panel associated with
a phenocopy of a cardiomyopathy. Pathogenic vari-
ants in the GLA gene cause Fabry disease, a lysosomal
storage disorder characterised by neuropathic pain,
angiokeratoma, chronic kidney disease, left ventricu-
lar hypertrophy (mimicking hypertrophic cardiomy-
opathy (HCM)), and cerebrovascular disease. Left
ventricular hypertrophy can also be the only disease
expression, especially in female carriers, and in carri-
ers of specific GLA variants known to cause a cardiac-
only phenotype. Patients suspected of HCM can
have a GLA variant and clinical Fabry disease. Our
patient, however, did not have HCM but DCM and
her variant was of unknown pathogenicity. Possible
explanations included a) that the GLA variant could
be a new variant giving rise to a cardiac-only pheno-
type for Fabry disease; b) that our patient had Fabry
disease with a DCM phenotype as an end-stage form
of Fabry-related HCM/left ventricular hypertrophy
[12]; or c) that the variant should be regarded as an
incidental finding unrelated to the patient’s pheno-
type. Because enzyme replacement can be effective
in Fabry disease, we had to decide whether to eval-
uate our patient for other features of Fabry disease,
and also, how to counsel the family. We discussed
the test result with our patient and asked for more
details on possible Fabry symptoms in her and other
relatives. She did not have any other symptoms of
Fabry disease and neither did any of her relatives. She
had two brothers who died suddenly in their forties,
which could fit with an X-linked inheritance, but they
were said to have no symptoms specific to Fabry dis-
ease. We therefore decided Fabry disease was unlikely
and considered the GLA variant an incidental finding.
Because her DCM could still be hereditary, we ad-
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vised regular cardiac evaluations for her first-degree
relatives and the first-degree relatives of the sudden
death victims in her family. Recently, this variant was
reclassified to a class 2 variant (unlikely pathogenic).
Reclassification was based on the frequency of this
variant in controls with a similar ethnic background
as our patient (53 times in 10,122 South Asian alleles)
and a relatively high enzyme activity (45% of wild-
type) in a functional study [13].
Likely pathogenic variant in combination with
a pathogenic variant
We performed DNA diagnostics using the cardiomy-
opathy gene panel in a middle-aged female with
HCM without a family history of cardiomyopathy or
sudden death. Her mother had developed atrial fib-
rillation at old age but showed no signs of HCM. We
detected a pathogenic variant in the MYBPC3 gene
(c.2149-2del, NM_000256.3), but also a class 4 vari-
ant (likely pathogenic) in the DSG2 gene (c.1143del;
p.(Asn381Lysfs*2), NM_001943.3). The MYBPC3 gene
is the most frequently mutated gene in HCM and
we found a clear pathogenic variant. Variants in
the DSG2 gene are mainly associated with arrhyth-
mogenic right ventricular cardiomyopathy (ARVC)
and not with HCM. Rare nonsynonymous variants in
desmosomal genes like DSG2 have been described in
HCM cohorts in up to 20% of cases, but most of them
are class 2 or 3 variants, often found in combination
with a sarcomeric variant [14, 15]. Alfares et al. do not
mention class 4 or 5 variants in desmosomal genes in
their large cohort of HCM patients [16]. Still, a class 4
variant in this gene should be taken seriously. This
specific DSG2 variant has not been described pre-
viously in literature and was not observed in about
120,000 alleles from the Exome Aggregation Consor-
tium (ExAC) database. Although this variant results in
a truncated protein, this does not imply it is certainly
pathogenic. Truncating variants in DSG2 are also ob-
served in controls, but about two times more frequent
in ARVC patients (https://cardiodb.org/ACGV/).
This test result could mean that a) the DSG2 vari-
ant contributes to the HCM phenotype of our pa-
tient; b) the patient now also has an increased risk
of ARVC; or c) the DSG2 variant is benign and does
not cause disease. We had to decide whether to offer
relatives predictive genetic testing for the MYBPC3
variant alone or for the DSG2 variant as well. The
risk of cardiac disease (ARVC or HCM) for relatives
only carrying the DSG2 variant remained unknown.
We therefore chose a practical approach and offered
the family of this patient predictive genetic testing for
both variants. Carriers of one or two of the variants
were advised to have regular cardiac evaluations.
Variant in a gene associated with other disease
A young infant showed signs of cardiomyopathy
(a combination of restrictive and dilated cardiomy-
opathy) and was tested using the cardiomyopathy
gene panel. We identified a clear pathogenic vari-
ant in the SCN5A gene (c.5228G>A; p.(Gly1743Glu),
NM_001099404.1). Although variants in SCN5A are
associated with dilated cardiomyopathy, this spe-
cific variant was known to be associated with Bru-
gada syndrome, not with DCM. The nucleotide
change c.5228G>A predicts the amino acid substi-
tution p.(Gly1743Glu) in the SCN5A protein. The vari-
ant changes a highly conserved amino acid (PolyPhen
HumDiv= 1 and HumVar= 1) and the chemical dif-
ference between Gly and Glu is moderate (Grantham
distance: 98 (0–215)). The variant has been described
in Brugada patients [17, 18]. Functional studies in
a heterologous expression system showed a reduced
sodium current compared with wildtype [19]. In ad-
dition, the variant was not observed in about 121,000
alleles from the ExAC database.
The detection of this SCN5A variant could mean:
a) that this child now (also) has Brugada syndrome: or
b) that this SCN5A variant can also cause DCM, pos-
sibly as an end-stage result of tachyarrhythmia. The
majority of Brugada syndrome patients are diagnosed
in their forties, but ECG abnormalities can already be
seen in childhood. Some variants have been associ-
ated with sudden infant death syndrome (SIDS). This
specific variant has not been described to result in
an atypical form of Brugada syndrome. Of note, our
DNA laboratory found this variant in several Brugada
patients, but also in one SIDS case. This child did not
show any arrhythmia or Brugada signs on the ECG
and was too young to perform a provocation test with
ajmaline or flecainide. DCM as an end-stage result
of a severe Brugada phenotype was therefore unlikely.
Clinically, the child does not have Brugada syndrome
yet, but is probably at risk of developing it. We de-
cided to first counsel the parents and offer them car-
diac evaluation and DNA testing to possibly support
our thoughts. The mother of the child showed signs
of Brugada syndrome on her ECG and DNA testing
showed that she was a carrier of the SCN5A variant.
We then concluded that the SCN5A variant was in-
deed related to Brugada syndrome in this family and
offered predictive genetic testing to the first-degree
relatives of the mother. All of them were tested and
several were found to be carrier of the SCN5A variant.
We assume the DCM of the infant is not explained
by the SCN5A variant and because we cannot exclude
a genetic cause, we advised cardiac evaluations to the
child’s parents and siblings.
Discussion
Our gene panels have an overall detection rate (class 3,
4, and 5 variants) of around 50%. Most of the detected
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variants are variants of uncertain significance. The
high frequency of these VUS (in about 30–40% of car-
diogenetic gene panel test results) necessitates pre-
test counselling on VUS of tested patients. In our
centre, all patients receive such pre-test counselling
by a genetic counsellor specialised in cardiogenetics
and with knowledge of (counselling) VUS. Still, we en-
countered unexpected results giving rise to challenges
in counselling and clinical decision making. We iden-
tified three types of challenging gene panel results:
1) one or more VUS in combination with a pathogenic
variant; 2) variants associated with another genetic
heart disease; and 3) variants associated with a syn-
drome involving cardiac features. Therefore, pre-
test counselling—even in disease-specific gene pan-
els—should not only include information on disease-
related VUS, but also on incidental findings (i. e. not
directly related with the disease tested for). In our
experience, and literature supports this, genetic test
results, especially VUS, are not only difficult to under-
stand for a patient, but are also often misinterpreted
by non-genetic physicians [20–22]. We therefore also
recommend pre-test and post-test counselling to be
performed by a physician/counsellor with sufficient
knowledge on VUS and variant classification. Knowl-
edge, understanding, and education on VUS and
other possible genetic test results are certainly areas
for further study.
As illustrated in the cases the unclear test results
are discussed in a multidisciplinary team to review
the case from different angles. This team consists
of clinical geneticists, cardiologists, clinical molecular
geneticists, and researchers all specialised in cardio-
genetics. Follow-up of patients and family members
may be necessary to evaluate decisions that have been
made. In our opinion it is important that physicians
requesting cardiogenetic NGS-based tests are involved
in or are in contact with such amultidisciplinary team.
Conclusions
The use of larger NGS-based gene panels does not
only increase the detection rates of pathogenic vari-
ants but also of multiple variants, variants of uncer-
tain significance and incidental findings. Such test
results, especially VUS and incidental findings, can
be challenging for genetic counselling and call for
proper pre-test and post-test counselling. We advise
the evaluation of challenging cases by a multidisci-
plinary team.
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